SaaS companies scale revenue not by adjusting price points, but by creating distinct packages for different segments. The same core software can be sold for vastly different amounts to enterprise versus mid-market clients by packaging features, services, and support to match their perceived value and needs.

The stickiest software is critical but inexpensive relative to a customer's overall budget, like payroll services. This 'Goldilocks zone' makes the software too small a cost for C-suite review, yet too embedded to easily replace, creating a powerful moat.

SaaS companies often use the traditional top-down sales funnel as their mental model. However, this model is fundamentally flawed because it ends at the 'close' and completely ignores the recurring revenue component, which is the lifeblood of SaaS. The 'bow tie' model is a more accurate representation.

Standard SaaS pricing fails for agentic products because high usage becomes a cost center. Avoid the trap of profiting from non-use. Instead, implement a hybrid model with a fixed base and usage-based overages, or, ideally, tie pricing directly to measurable outcomes generated by the AI.

Investors and acquirers pay premiums for predictable revenue, which comes from retaining and upselling existing customers. This "expansion revenue" is a far greater value multiplier than simply acquiring new customers, a metric most founders wrongly prioritize.

Buyers pay a premium for predictable income, not just high revenue. Even non-SaaS businesses, like a home builder, can create valuable "durable revenue" by adding contract-based services like lawn care, significantly increasing enterprise value.

Selling low-cost vaccines to organizations like Gavi isn't just charity for pharmaceutical companies. It creates massive economies of scale, lowering the cost of goods for their high-margin primary markets and increasing overall net profit, creating a powerful win-win incentive structure.

The macroeconomic shift to a high-margin, high-interest-rate environment means SaaS companies must abandon the 'growth at all costs' playbook. Pricing decisions, such as usage-based models that delay revenue, have critical cash flow implications. Strategy must now favor profitability and immediate cash generation.

The future of biotech moves beyond single drugs. It lies in integrated systems where the 'platform is the product.' This model combines diagnostics, AI, and manufacturing to deliver personalized therapies like cancer vaccines. It breaks the traditional drug development paradigm by creating a generative, pan-indication capability rather than a single molecule.